摘要
目的:探究培美曲塞联合卡铂治疗晚期肺腺癌的效果,以及对肿瘤标志物水平的影响。方法:选择2016年5月—2019年5月本院治疗的84例晚期肺腺癌患者作为研究对象,根据治疗方案不同将患者分为观察组48例和对照组36例。观察组采用培美曲塞联合卡铂治疗,对照组采用多西他赛联合卡铂治疗。比较两组临床疗效、不良反应发生情况及实验室指标[血清细胞角蛋白19片段(CYFRA21-1)、糖抗原19-9(CA199)和组织多肽特异性抗原(TPS)水平]。结果:治疗后,观察组客观缓解率(ORR)和疾病控制率(DCR)高于对照组(P<0.05);观察组疲劳、厌食、恶心、呕吐、腹痛发生率高于对照组(P<0.05);但观察组白细胞减少、贫血、ALT/AST升高发生率低于对照组(P<0.05)。两组不良反应总发生率比较,差异无统计学意义(P>0.05);观察组治疗后3个月血清CYFRA21-1、CA199、TPS含量低于对照组(P<0.05)。结论:培美曲塞联合卡铂治疗晚期肺腺癌的效果良好,可降低肿瘤细胞因子表达,安全性较高。
Objective: To explore the efficacy and safety of pemetrexed combined with carboplatin in the treatment of advanced lung adenocarcinoma, as well as the influence on the level of tumor markers. Methods: A total of 84 patients with advanced lung adenocarcinoma who were treated in our hospital from May 2016 to May 2019 were selected as the study objects. According to different treatment regimens, the patients were divided into observation group(48 cases) and control group(36 cases). The observation group was treated with pemetrexed combined with carboplatin, and the control group was treated with docetaxel combined with carboplatin. The clinical efficacy, occurrence of adverse reactions and laboratory indexes(serum cytokeratin 19 fragment(CYFRA21-1), glycoantigen 19-9(CA199) and tissue polypeptide specific antigen(TPS) levels) were compared between the two groups. Results: After treatment, the objective response rate(ORR) and disease control rate(DCR) in the observation group were higher than those in the control group(P<0.05). The incidence of fatigue, anorexia, nausea, vomiting and abdominal pain in observation group was higher than that in control group(P<0.05).However, the incidence of leukopenia, anemia and elevated ALT/AST in observation group was lower than that in control group(P<0.05). There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05). The contents of CYFRA21-1, CA199 and TPS in serum in the observation group were lower than those in the control group(P<0.05). Conclusion: Pemetrexed combined with carboplatin has good efficacy in the treatment of advanced lung adenocarcinoma, which can reduce the expression of tumor cytokines and has high safety.
作者
杨晓平
张小卿
YANG Xiaoping;ZHANG Xiaoqing(Department of Respiratory Medicine,the First Hospital of Jianyang in Nanping City,Nanping 354200,Fujian,China;Department of Oncology,the First Hospital of Jianyang in Nanping City,Nanping 354200,Fujian,China)
出处
《中国药物滥用防治杂志》
CAS
2022年第12期1831-1834,共4页
Chinese Journal of Drug Abuse Prevention and Treatment
关键词
肿瘤标志物
培美曲塞
卡铂
肺腺癌
Tumor markers
Pemetrexed
Carboplatin
Lung adenocarcinoma
